# üß¨ü¶† HIV-1 and Neutralizing Antibodies: A Battle for Control

## Team 4 - Irun Cohen

**Members:**
- Shea Mowry
- Han Kahvecioglu
- Maya Bartels
- Felipe Munoz
- Meghan Pinter

This team will explore the coexistence of broadly neutralizing antibodies (bNAbs) and antibody-sensitive viruses in an HIV-1 infected individual who has maintained low viral loads for over 30 years. They will focus on the mechanisms by which bNAbs contribute to viral control and the implications for designing effective HIV vaccines.

---

## Presentation Overview

**Topic:** *HIV-1 and Neutralizing Antibodies: A Battle for Control*  
**Paper Reference:**
- Natalia T. Freund, Haoqing Wang, Louise Scharf, et al.
- *Sci Transl Med* 2017; 9(373): eaal2144
- DOI: [10.1126/scitranslmed.aal2144](https://doi.org/10.1126/scitranslmed.aal2144)

### Abstract Summary üìÑ

The study describes an HIV-1 controller with the HLA-B57*01 and HLA-B27*05 alleles who maintained low viral loads for 30 years. The individual developed broad and potent neutralizing antibodies (bNAbs) that target multiple non-overlapping sites on the HIV-1 envelope trimer. Among these, BG18 is an antibody directed at the glycan-V3 portion of the HIV-1 envelope, representing the most potent member of its class. Single-genome sequencing revealed that 88.5% of circulating viruses remained sensitive to at least one of the coincident bNAbs. These findings suggest that combinations of bNAbs could be used to control HIV-1 infection, with potential implications for HIV vaccine development.

---

## Activities üìö

1. **30-Minute Presentation by Team Cohen (Until 4:00 PM)**  
   Team Cohen will present their analysis of the coexistence of bNAbs and antibody-sensitive viruses in HIV-1 infection. They will delve into the mechanisms of antibody-mediated control and the challenges involved in designing effective HIV vaccines.

2. **30-Minute Group Discussion (4:00 PM - 4:30 PM)**  
   The class will engage in a detailed discussion of how bNAbs contribute to viral control and what obstacles remain in the pursuit of an effective HIV vaccine. This will include a review of how the body generates bNAbs and why some viruses remain antibody-sensitive despite ongoing immune pressure.

3. **Team Tasks: Designing Effective HIV Vaccines (4:30 PM - 5:15 PM) üí¨**

---

### 3A: How do broadly neutralizing antibodies (bNAbs) affect HIV vaccine design?

![Strategies to Design bNAb HIV Vaccines](https://github.com/atomiclaboratory/systems_immunology_course_2024/blob/main/Course%20Materials/MODULE%203%20-%20Weeks%204-6/team%204%20Irun%20Cohen/reading%20materials/Strategies%20design%20bnAb%20HIV.png)

*Adopted from: Haynes, B.F., Wiehe, K., Borrow, P. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol 23, 142‚Äì158 (2023). [DOI: 10.1038/s41577-022-00753-w](https://doi.org/10.1038/s41577-022-00753-w)*

The image summarizes strategies for designing vaccines that induce HIV-1 broadly neutralizing antibodies (bNAbs). The process starts by studying the B cells of an HIV-1-infected person who naturally produces bNAbs. Researchers sequence the B cell receptors (BCRs) to trace how these antibodies evolve from their original form (called the unmutated common ancestor or UCA) to mature bNAbs. Using this information, vaccines are designed to guide the immune system along the same evolutionary path to produce bNAbs. üß¨

Key approaches include:

- **üß† Germline-targeting:** Designing early vaccine components to bind to the UCA form of B cells, using specially selected or modified HIV envelope proteins (Env).
- **üî¨ Mutation-guided design:** Identifying critical mutations needed for bNAbs and designing vaccines that encourage B cells to evolve in that direction.
- **üìê Structure-based design:** Using detailed models of how bNAbs bind to HIV to improve vaccine components.

The goal is to create a sequence of vaccines that help B cells evolve into bNAb producers, providing protection against a wide range of HIV strains. üíâü¶†

**Hypothetical Study: HIV Vaccine Development Based on bNAb Responses**

- **Study Design:**  
  Researchers are developing a vaccine aimed at inducing bNAb responses in individuals at risk for HIV. The vaccine uses a combination of envelope glycoproteins from different HIV-1 strains to broaden the immune response. The primary outcome of interest is the generation of bNAbs that neutralize a wide range of HIV-1 strains.

**Key Considerations:**

- **Immunogenicity of Envelope Glycoproteins:**  
  How do different glycoproteins influence the generation of bNAbs, and what factors should be considered when choosing these antigens?

- **Autologous vs. Heterologous Strains:**  
  Should the vaccine target the individual's own viral strains (autologous) or a wide range of strains (heterologous)? How does this choice impact vaccine efficacy?

- **Combinations of bNAbs:**  
  What are the benefits and challenges of using combinations of bNAbs to control HIV, as shown in the study?

---

### 3B: What are the challenges in inducing bNAbs through vaccination?

Researchers have found that inducing bNAbs through vaccination is difficult due to the immune system's tendency to favor antibody responses to variable regions of the virus. Discuss why bNAbs are rare and the implications for vaccine design.

**Answer:**  
bNAbs target conserved regions of the HIV-1 envelope, which are often shielded by glycan structures or undergo rapid mutation. The immune system's tendency to focus on variable regions, which change frequently, makes it difficult to produce bNAbs that can neutralize a wide variety of viral strains. Vaccine strategies must therefore aim to focus immune responses on these conserved regions, potentially through sequential immunization or the use of stabilized envelope proteins.

---

### 3C: Using AlphaFold to Improve HIV Vaccine Design

1. **What is AlphaFold?**  
   AlphaFold is an AI-based tool developed by DeepMind that predicts the three-dimensional structure of proteins with high accuracy based on their amino acid sequences. Understanding these structures is crucial for designing vaccines, as protein shape dictates how the immune system recognizes and neutralizes pathogens.

   - Learn more about AlphaFold: [AlphaFold website](https://alphafold.com/)

2. **How to Use AlphaFold:**  
   Learn how to input protein sequences into AlphaFold to obtain structural predictions. Explore how these predictions can be applied to research in immunology, particularly in understanding the structure of HIV envelope proteins and bNAbs like BG18.

   - Tutorial on using AlphaFold: [Online AlphaFold tutorial](https://www.ebi.ac.uk/training/online/courses/alphafold/)

3. **Using AlphaFold in the Context of This Study:**  
   Discuss how AlphaFold can model the structure of HIV envelope proteins or bNAbs to predict which viral regions are most vulnerable to immune attack. Explore how this information could be used to design vaccine candidates that target these conserved regions more effectively.

4. **Improving HIV Vaccines with AlphaFold:**  
   Using AlphaFold‚Äôs structural predictions, researchers can refine the design of HIV vaccines by focusing on conserved regions of the virus that bNAbs can target. This approach can enhance vaccine effectiveness by ensuring the vaccine induces antibodies that neutralize a wide variety of HIV-1 strains.

---

## Tools and Approaches üîß

- **AlphaFold (Protein structure prediction):**  
  [AlphaFold website](https://alphafold.com/) | [AlphaFold Tutorial](https://www.ebi.ac.uk/training/online/courses/alphafold/)

- **OpenFold (Retraining AlphaFold for new insights):**  
  - [OpenFold Documentation](https://openfold.readthedocs.io/en/latest/Inference.html)
  - [OpenFold GitHub Repository](https://github.com/aqlaboratory/openfold)
  - Citation: Ahdritz, G., Bouatta, N., Floristean, C. et al. *OpenFold: retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization.* Nat Methods 21, 1514‚Äì1524 (2024).  
    [DOI: 10.1038/s41592-024-02272-z](https://doi.org/10.1038/s41592-024-02272-z)

---

## Relevant Reading üìñ

1. **AlphaFold's breakthrough paper:**  
   Jumper, J., Evans, R., Pritzel, A., et al. *Highly accurate protein structure prediction with AlphaFold.* Nature 596, 583‚Äì589 (2021).  
   [DOI: 10.1038/s41586-021-03819-2](https://doi.org/10.1038/s41586-021-03819-2)

2. **OpenFold's development and retraining insights:**  
   Ahdritz, G., Bouatta, N., Floristean, C. et al. *OpenFold: retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization.* Nat Methods 21, 1514‚Äì1524 (2024).  
   [DOI: 10.1038/s41592-024-02272-z](https://doi.org/10.1038/s41592-024-02272-z)

3. **AlphaFold Protein Structure Database (2024 Update):**  
   Providing structure coverage for over 214 million protein sequences.  
   *Nucleic Acids Research*, Volume 52, Issue D1, 5 January 2024, Pages D368‚ÄìD375.  
   [DOI: 10.1093/nar/gkad1011](https://doi.org/10.1093/nar/gkad1011)